Europe’s largest pharmaceutical firm, Novo Nordisk, has announced that it will offer its most popular weight-loss drug, Wegovy, for less than half of its listed price. This follows a similar ...

Novo Nordisk stock has fallen roughly 40% from a peak it reached last June. The U.S. Food and Drug Administration recently confirmed Novo Nordisk is producing enough Ozempic and Wegovy to meet ...

Former partner and executive director at independent advisory firm KordaMentha, Tony Vizza, has launched Australian digital risk management advisory firm Novera. Novera's suite of services will ...

How does a nation remember its artists? "What Novera is doing now will take us a long time to understand," said legendary artist Zainul Abedin, decades ago. On Thursday (February 27) evening ...

Pharmaceutical manufacturer Novo Nordisk on Wednesday announced it will be offering a direct-to-patient program for uninsured and underinsured individuals to be able to pay cash for its weight ...

The FDA today declared the national deficit of GLP-1 diet drugs at an end. Well, at least for Novo Nordisk's Ozempic and Wegovy. Novo Nordisk sales should be going up, and Hims & Hers Health's ...

Danish drugmaker Novo Nordisk (NVO) said Wednesday that it will drop prices 23% for all doses of Wegovy. The new monthly price of $499, down from $650, takes effect immediately. Novo said the new ...

Novo Nordisk is cutting the cost of its blockbuster weight-loss drug Wegovy in half for U.S. patients paying cash through its direct-to-patient online pharmacy, as competition in the highly ...

Novo Nordisk (NVO) announced a new cash-pay option for its blockbuster weight-loss drug Wegovy, offering a monthly dose at $499 and home delivery. The move follows competitor Eli Lilly (LLY ...

Novo Nordisk will start selling its obesity drug Wegovy directly to patients at a reduced price, following a similar move from Eli Lilly as the two drugmakers compete for market share and try to ...

After its potential kidney disease drug went down in flames late last year, Novo Nordisk is pinning the blame on alleged fraudulent claims by the drug’s original maker. The Danish pharma giant ...